The Johnson & Johnson (JNJ) Stake Decreased by Moon Capital Management LLC

The Johnson & Johnson (JNJ) Stake Decreased by Moon Capital Management LLC

Moon Capital Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,677 shares of the company’s stock after selling 100 shares during the period. Johnson & Johnson accounts for 0.9% of Moon Capital Management LLC’s holdings, making the stock its 27th largest position. Moon Capital Management LLC’s holdings in Johnson & Johnson were worth $689,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Americafirst Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $101,000. Capital Asset Advisory Services LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $202,000. D. Scott Neal Inc. increased its position in Johnson & Johnson by 4.1% in the second quarter. D. Scott Neal Inc. now owns 1,840 shares of the company’s stock valued at $223,000 after buying an additional 72 shares during the period. Terra Nova Asset Management LLC bought a new position in Johnson & Johnson during the first quarter valued at approximately $243,000. Finally, Pure Financial Advisors Inc. bought a new position in Johnson & Johnson during the second quarter valued at approximately $355,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.59% on Friday, hitting $117.56. The stock had a trading volume of 5,640,519 shares. The stock has a 50 day moving average of $118.72 and a 200 day moving average of $117.37. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The firm has a market cap of $321.63 billion, a price-to-earnings ratio of 21.91 and a beta of 0.62.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The business earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. Equities analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

Several research analysts have recently commented on the company. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. BMO Capital Markets reiterated an “outperform” rating and set a $132.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 11th. Jefferies Group increased their target price on Johnson & Johnson from $113.00 to $119.00 and gave the stock a “hold” rating in a research report on Thursday, August 4th. Finally, Deutsche Bank AG reiterated a “hold” rating and set a $142.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Thursday, July 21st. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $120.19.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment